CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 74 enrolled
Drug / intervention
vareniclinedrug
Likely dose
varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02854800
NCT02854800Phase 3Completed
CompareCT.gov

Smoking Cessation & Opioid Dependence Treatment Integration: Does Timing Matter?

West Virginia University·interventional·Posted Aug 3, 2016·Updated Aug 14, 2020

In Brief

A Phase 3 clinical trial evaluating varenicline for Smoking Cessation and Opioid Related Disorders. Completed, enrolled 74 participants across 1 site.

Detailed Summary

The primary purpose of this study was to examine the feasibility of integrating a smoking cessation intervention for cigarette smokers enrolled in an outpatient program for opioid dependence. The secondary purpose was to compare treatment effects as a function of phase in the outpatient program: 0-90 days (weekly attendance), 90 days-1 year (biweekly attendance), and more than 1 year (monthly attendance).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation, Opioid Related Disorders
CountriesUnited States
CollaboratorsPfizer, National Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 3, 2016
Enrollment StartJul 8, 2016
Primary CompletionApr 10, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.9 years ago

Interventions

vareniclinedrug

Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).